Halozyme Therapeutics price to sales ratio HALO

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026: 8.6×
10-year median: 10.2×
Against its 10-year history: 44th; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.2× to 33.8×
Peer median: 6.8×

Halozyme Therapeutics' price to sales ratio is 8.6× as of Oct 23, 2026.

That is below its ten-year median of 10.2×, close to the middle of its last ten years.

Over that time it ranged from 5.2× in Mar 2026 to 33.8× in Feb 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

median 10.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.6×	5.2×	8.6×
2025	6.5×	5.9×	7.9×
2024	6.5×	5.7×	9.3×
2023	6.3×	5.7×	12.9×
2022	13.3×	9.9×	15.1×
2021	12.2×	9.9×	33.8×
2020	28.9×	11.0×	29.1×
2019	13.0×	7.6×	16.8×
2018	7.3×	7.1×	17.5×
2017	17.4×	9.2×	18.8×
2016	8.0×	6.9×	16.8×
2015	19.6×	1.7×	38.3×
2014	21.0×	16.3×	31.3×
2013	27.1×	13.8×	40.8×
2012	32.7×	9.3×	34.4×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

Company	Price to sales ratio
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
TECHBIO-TECHNE	9.4×
RGENRepligen	12.7×
KRYSKrystal Biotech	20.9×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
ALNYAlnylam Pharmaceuticals	6.2×
ONCBeOne Medicines	7.0×
REGNRegeneron Pharmaceuticals	5.3×
Peer median	6.8×

Where Halozyme Therapeutics ranks

#38of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.